![Yanni Lin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Yanni Lin has founded Suzhou Kerui Gene Biotechnology Co., Ltd.
in 2016 and currently holds the title of Chief Scientist.
Yanni Lin active positions
Companies | Position | Start |
---|---|---|
Suzhou Kerui Gene Biotechnology Co., Ltd.
![]() Suzhou Kerui Gene Biotechnology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Suzhou Kerui Gene Biotechnology Co., Ltd., also known as Cure Genetics, is a biotech company founded in 2016 by Yuan Yuan Xu, Meng Yuan Liu, and Yanni Lin. The company is based in Suzhou, China. Cure Genetics is committed to expanding the frontier of gene therapy through its innovative technology of gene editing and gene delivery. With its world-leading AAV manufacturing capability, Cure Genetics' proprietary Velptm platform enables a fast yet systematic design, selection, and optimization of AAV vectors with special features and significantly better performance of in vivo gene delivery. The Chinese company aims to provide effective treatment options for patients worldwide with unmet medical needs and to establish itself as a benchmark in the field of cell and gene therapy. | Founder | 01/07/2016 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Suzhou Kerui Gene Biotechnology Co., Ltd.
![]() Suzhou Kerui Gene Biotechnology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Suzhou Kerui Gene Biotechnology Co., Ltd., also known as Cure Genetics, is a biotech company founded in 2016 by Yuan Yuan Xu, Meng Yuan Liu, and Yanni Lin. The company is based in Suzhou, China. Cure Genetics is committed to expanding the frontier of gene therapy through its innovative technology of gene editing and gene delivery. With its world-leading AAV manufacturing capability, Cure Genetics' proprietary Velptm platform enables a fast yet systematic design, selection, and optimization of AAV vectors with special features and significantly better performance of in vivo gene delivery. The Chinese company aims to provide effective treatment options for patients worldwide with unmet medical needs and to establish itself as a benchmark in the field of cell and gene therapy. | Commercial Services |
- Stock Market
- Insiders
- Yanni Lin